| abstract |
The present invention relates to oral administration of taxane anti-tumor agents, which have had low or no oral bioavailability, to oral administration to human patients suffering from taxane-reactive disease symptoms and that the therapeutic blood levels are sufficiently available in vivo. . In a preferred embodiment the taxanes, preferably paclitaxel, are co-administered to the patient with a cyclosporin enhancer, preferably cyclosporin A for oral administration. In a preferred method, the enhancer is administered about 0.5-72 hours prior to the taxane administration and the secondary enhancer, and immediately before, concurrently or immediately after the taxane administration. The present invention also provides methods for the treatment of human patients suffering from taxane-reactive disease symptoms, as well as methods for providing such treatment while preventing or alleviating hypersensitivity and allergic reactions without predose. |